SCHEMBL5654773

SCHEMBL5654773

CC1(C)CC(NC(=O)c2ccc(-c3nc4ncccc4[nH]3)s2)CC(C)(C)N1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.41
PBK Q96KB5 2/20 0.41
EZH2 Q15910 4/20 0.40
HPSE Q9Y251 1/20 0.40
MEN1 O00255 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
PRMT5 O14744 1/20 0.39
PDE5A O76074 1/20 0.38
POLB P06746 1/20 0.38
HSD17B10 Q99714 2/20 0.38
GLA P06280 1/20 0.38
KDM4E B2RXH2 1/20 0.37
NPC1 O15118 1/20 0.37
TP53 P04637 1/20 0.37
MAPT P10636 1/20 0.37
HPGD P15428 1/20 0.37
RAB9A P51151 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5651508 0.81 KMT2A (0.46) KMT2AEZH2MEN1L3MBTL1POLB
SCHEMBL5651253 0.77 GLA (0.55) KMT2AEZH2MEN1L3MBTL1POLB
SCHEMBL5653411 0.77 POLB (0.40) KMT2AEZH2MEN1L3MBTL1POLB
SCHEMBL5650497 0.77 L3MBTL1 (0.51) KMT2AEZH2MEN1L3MBTL1PDE5A
SCHEMBL5652551 0.77 GLA (0.47) KMT2AEZH2MEN1L3MBTL1PDE5A
SCHEMBL5654768 0.76 KMT2A (0.39) KMT2AEZH2HPSEMEN1L3MBTL1
SCHEMBL5654114 0.75 PDE2A (0.53) KMT2AEZH2MEN1L3MBTL1PDE5A
SCHEMBL5654880 0.74 AURKA (0.45) PBKHPSEPRMT5PDE5A
SCHEMBL5652880 0.74 KMT2A (0.41) KMT2AEZH2MEN1L3MBTL1POLB
SCHEMBL5648762 0.74 PDE5A (0.51) KMT2AEZH2MEN1L3MBTL1PDE5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7220769-B2 Azolylbenzamides and analogues and their use for treating osteoporosis NIKEM RESEARCH S.R.L. (IT) 2007-05-22 US disclosed
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis 3-V BIOSCIENCES, INC. 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis NR0B2, NR0B1, NCOR1 KMT2A 439/4885PBK 4737/4885EZH2 879/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.